<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04867915</url>
  </required_header>
  <id_info>
    <org_study_id>CLL2121</org_study_id>
    <nct_id>NCT04867915</nct_id>
  </id_info>
  <brief_title>Study on the Diagnosis and Management of CLL in Italy by GIMEMA</brief_title>
  <official_title>Observational Study on the Diagnosis and Management of Chronic Lymphocytic Leukemia (CLL) in Italy by Gruppo Italiano Malattie EMatologiche Dell'Adulto (GIMEMA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      retrospective and prospective multicenter observational clinical and biological data&#xD;
      collection from all patients with newly diagnosed CLL, SLL or MBL.&#xD;
&#xD;
      retrospective cohort: all cases with a diagnosis between January 1st 2010 and August 31th&#xD;
      2021.&#xD;
&#xD;
      prospective cohort: all patients with a diagnosis between September 1st 2021 and September&#xD;
      1st 2025.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective and prospective multicenter observational study designed by the&#xD;
      Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA). The study consists of clinical&#xD;
      and biological data collection from all patients with newly diagnosed CLL, SLL or MBL&#xD;
      (according to the WHO 2007 and 2018 diagnostic criteria). The retrospective part aims at&#xD;
      including all cases followed at participating centers with a diagnosis between January 1st&#xD;
      2010 and August 31th 2021 (planned study initiation), while the prospective part will include&#xD;
      all patients with a documented diagnosis of CLL, SLL or MBL between September 1st 2021 and&#xD;
      September 1st 2025 by the first immunophenotypic/histological evaluation. The data is&#xD;
      collected through electronic case report form accessible by the participating centers on a&#xD;
      dedicated platform.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the diagnosis and management of CLL patients</measure>
    <time_frame>at 1 year for the prospective cohort and at 4 years for the retrospective cohort</time_frame>
    <description>evaluation of CLL management in terms of time to first treatment</description>
  </primary_outcome>
  <enrollment type="Anticipated">12500</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <condition>MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with CLL/SLL or MBL diagnosis followed at participant sites starting from&#xD;
        January 1st, 2010 (retrospective cohort) and from September 1st, 2021 (prospective cohort).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥18 years at diagnosis&#xD;
&#xD;
          2. One of the following diagnoses that meet the international diagnostic criteria&#xD;
             (iwCLL2018 and WHO2017)&#xD;
&#xD;
               1. Chronic lymphocytic leukemia (CLL)&#xD;
&#xD;
               2. Small lymphocytic lymphoma (SLL)&#xD;
&#xD;
               3. CLL-like monoclonal B-cell lymphocytosis (MBL)&#xD;
&#xD;
          3. Retrospective cohort: CLL/SLL/MBL diagnosis between January 1st 2010 and August 31th&#xD;
             2021.&#xD;
&#xD;
          4. Prospective cohort: CLL/SLL/MBL diagnosis between September 1st 2021 and September&#xD;
             1st, 2025.&#xD;
&#xD;
          5. Signed written informed consent according to ICH/EU/GCP and national local laws (if&#xD;
             applicable)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

